GSK exits Ebola vaccine R&D as J&J rival starts Uganda trialGlaxoSmithKline has licensed vaccines for Ebola to the US Sabin Vaccine Institute, just as a major trial of Share XGSK exits Ebola vaccine R&D as J&J rival starts Uganda trialhttps://pharmaphorum.com/news/gsk-exits-ebola-vaccine-rd-as-jj-rival-starts-uganda-trial/
Bayer aims at J&J and Pfizer with new prostate cancer drugThe FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease Share XBayer aims at J&J and Pfizer with new prostate cancer drughttps://pharmaphorum.com/news/bayer-aims-at-jj-and-pfizer-with-new-prostate-cancer-drug/
J&J faces FTC probe on Remicade biosimilar defenceJohnson & Johnson’s antibody blockbuster Remicade has proved highly resistant to biosimilar competition – so much so that Share XJ&J faces FTC probe on Remicade biosimilar defencehttps://pharmaphorum.com/news/jj-faces-ftc-probe-on-remicade-biosimilar-defence/
EMA starts review of Xtandi in hormone-sensitive prostate cancerThe EU regulator has started the clock ticking on its review of Pfizer and Astellas’ prostate cancer drug Share XEMA starts review of Xtandi in hormone-sensitive prostate cancerhttps://pharmaphorum.com/news/ema-starts-review-of-xtandi-in-hormone-sensitive-prostate-cancer/
J&J warns generics will bite its pharma unit in the second halfJohnson & Johnson has kicked off the interim results season with a warning that low-cost generic and biosimilar Share XJ&J warns generics will bite its pharma unit in the second halfhttps://pharmaphorum.com/news/jj-warns-generics-will-bite-its-pharma-unit-in-the-second-half/
All eyes on Oklahoma as J&J awaits $17bn opioid case verdictThe multibillion dollar opioid liability lawsuit filed by the state of Oklahoma against Johnson & Johnson came to Share XAll eyes on Oklahoma as J&J awaits $17bn opioid case verdicthttps://pharmaphorum.com/news/all-eyes-on-oklahoma-as-jj-awaits-17bn-opioid-case-verdict/
GSK hires former Genentech expert for AI unitGlaxoSmithKline has hired computational drug design specialist Dr Kim Branson to expand its artificial intelligence and machine learning Share XGSK hires former Genentech expert for AI unithttps://pharmaphorum.com/news/gsk-hires-former-genentech-expert-for-ai-unit/
FDA reviews Sanofi’s multiple myeloma drug isatuximabThe FDA has begun its review of Sanofi’s multiple myeloma drug isatuximab, as the French pharma prepares for Share XFDA reviews Sanofi’s multiple myeloma drug isatuximabhttps://pharmaphorum.com/news/fda-reviews-sanofis-multiple-myeloma-drug-isatuximab/
Bayer/J&J eye new paediatric use for anticoagulant XareltoBayer and Johnson & Johnson’s Xarelto (rivaroxaban) has been shown to prevent recurrence of thromboembolism in children, paving Share XBayer/J&J eye new paediatric use for anticoagulant Xareltohttps://pharmaphorum.com/news/bayer-jj-eye-new-paediatric-use-for-anticoagulant-xarelto/
